---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-262615"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T21:53:24.940108+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verrica launches underwritten public offering of common stock and warrants

## Summary
- Offering of common stock (or pre-funded warrants) and accompanying warrants; Jefferies sole bookrunner; 30-day option for 15% additional.
- Terminated ATM equity prospectus; no shares had been issued under the Open Market Sales Agreement with Jefferies.
- Targeting monthly operating cash flow break-even in H2 2025 after restructuring sales force from 80 to ~33 territories.
- Phase 2 data for VP-315 in BCC: 86% tumor size reduction, 51% complete histological clearance (n=90); End-of-Phase 2 meeting planned H1 2025.

## SEC filing metadata
- accession: 0001193125-24-262615
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524262615/0001193125-24-262615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524262615/d907739d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-262615
- JSON: https://secwatch.observer/filing/0001193125-24-262615.json
- Plain text: https://secwatch.observer/filing/0001193125-24-262615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.